Private Prescription Wegovy Mounjaro Dose Schedules Explained
Private Prescription Wegovy Mounjaro Dose Comparison: NHS vs Private Routes
The private prescription route for Wegovy Mounjaro dose comparison eliminates NHS barriers that often delay treatment for months. NHS patients require GP referral to specialist weight management services, face strict eligibility criteria, and endure waiting lists exceeding 6 months in many regions. Private assessment through EverydayMeds takes 3 minutes online, with prescriber review within 24-48 hours and next-day delivery once approved.
Both treatments remain prescription-only medicines requiring clinical oversight, but private access ensures immediate availability of genuine manufacturer stock. The same Novo Nordisk Wegovy supplied via NHS costs £79.99 privately for initial 0.25mg dose, whilst Mounjaro follows different pricing due to its newer dual-agonist mechanism. This Wegovy Mounjaro dose comparison reveals why many patients choose private treatment despite cost considerations.
Wegovy Mounjaro Dose Comparison: Complete Pricing Structure
Understanding the Wegovy Mounjaro dose comparison requires examining each medication's escalation schedule and associated costs. Wegovy follows a structured 20-week escalation: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), reaching maintenance 2.4mg (£209.99). Our Getting Started bundles like Intro Duo (0.25mg & 0.5mg) cost £169.99, providing seamless dose progression. Mounjaro uses different escalation intervals and pricing reflecting its dual GIP+GLP-1 mechanism.
New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Three-pen Take-It-Slow bundles accommodate patients needing extended dose periods, with Ultimate Stability Trio providing 3 months of 2.4mg maintenance for £649.99. This Wegovy Mounjaro dose comparison highlights how bundle pricing ensures treatment continuity without supply interruptions across different dose escalation requirements.
Clinical Evidence in Wegovy Mounjaro Dose Comparison Studies
The Wegovy Mounjaro dose comparison draws from separate clinical programmes due to different development timelines. Wegovy's STEP trials demonstrated significant outcomes: STEP 1 showed approximately 15% average weight reduction at 68 weeks versus 2.4% with placebo, whilst STEP 5 maintained 15.2% reduction at 2 years (Wilding et al., NEJM, 2021). These studies involved patients taking Wegovy alongside reduced-calorie diet and increased physical activity.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual-agonist approach, though direct head-to-head comparison with Wegovy remains limited due to different trial designs and patient populations. Both medications require clinical assessment to determine suitability, with prescribers considering individual patient factors beyond published trial data when conducting Wegovy Mounjaro dose comparisons for treatment selection.
How Wegovy Works in Wegovy Mounjaro Dose Comparison
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics naturally occurring incretin hormones regulating appetite and glucose metabolism. The medication works primarily in brain appetite centres, promoting feelings of fullness after smaller meals and potentially reducing food cravings between meals. This mechanism requires gradual dose escalation over 20 weeks, allowing patients to adapt to appetite changes whilst minimising side effects. Weekly injections using FlexTouch pre-filled pens maintain consistent medication levels, supporting sustained appetite regulation. Understanding this mechanism proves crucial when conducting Wegovy Mounjaro dose comparisons, as tirzepatide's dual-agonist approach targets additional pathways beyond GLP-1 receptors alone.
Ordering Process for Wegovy Mounjaro Dose Comparison Assessment
Our streamlined private prescription process eliminates traditional barriers whilst maintaining clinical safety standards required for both medications. The 3-minute online assessment captures medical history, current medications, weight management goals, and contraindication screening relevant to your Wegovy Mounjaro dose comparison needs. Qualified prescribers review applications within standard 3 working days, or 24 hours via express service, determining medication suitability based on MHRA licensing criteria and individual patient factors. Once approved, next-day delivery uses cold-chain temperature-controlled packaging maintaining medication integrity during transit. This process operates under GPhC registration #9012878, ensuring pharmaceutical standards equivalent to traditional pharmacy services whilst offering superior convenience and speed.
Storage Considerations in Wegovy Mounjaro Dose Comparison
Storage requirements represent a practical advantage in Wegovy Mounjaro dose comparison, particularly for frequent travellers or those with limited refrigeration access. Both medications require refrigerated storage (2-8°C) before first use, but Wegovy tolerates room temperature storage for 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy more suitable for extended travel or emergency situations where refrigeration becomes unavailable. FlexTouch pen design eliminates dose measurement concerns, with pre-filled syringes containing exact doses throughout the escalation schedule from 0.25mg to maintenance 2.4mg. Proper storage maintains medication potency and safety, regardless of which option emerges from your Wegovy Mounjaro dose comparison analysis.
Private Prescription Advantages for Wegovy Mounjaro Dose Comparison Decision-Making
Private prescription access uniquely supports informed Wegovy Mounjaro dose comparison by eliminating external pressures affecting NHS prescribing decisions. NHS formulary restrictions, budget constraints, and waiting list management can influence treatment recommendations beyond pure clinical considerations. Private prescribers focus solely on individual patient suitability, discussing both options transparently without external limitations affecting their professional judgement.
Additionally, private prescription allows flexible switching between treatments if initial selection proves unsuitable, something often complicated within NHS pathways requiring fresh referrals and additional waiting periods. This flexibility proves invaluable when Wegovy Mounjaro dose comparison reveals patient-specific factors favouring alternative treatment approaches, enabling rapid adjustment rather than prolonged unsuitable therapy continuation due to system constraints.
Making Your Wegovy Mounjaro Dose Comparison Decision
Your final Wegovy Mounjaro dose comparison should consider mechanism differences (single vs dual agonist), dosing schedules, storage requirements, and individual lifestyle factors affecting treatment adherence. Both remain prescription-only medicines requiring ongoing clinical supervision, available through our GPhC-registered service with transparent pricing and rapid access eliminating NHS delays. Use discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout to access competitive pricing starting from £79.99 for initial treatment. Our clinical team supports your treatment journey with ongoing monitoring and dose adjustment guidance, ensuring optimal outcomes regardless of your Wegovy Mounjaro dose comparison conclusion. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, with qualified prescribers available to discuss both treatment options based on your individual circumstances and medical history.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
